Amanote Research
Register
Sign In
Pcn184 - Cost-Effectiveness of Nivolumab Plus Ipilimumab in Advanced Melanoma
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.267
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
B. Tibet
Publisher
Elsevier BV
Related search
Cost-Effectiveness of Nivolumab in Combination With Ipilimumab in First-Line Treatment of Advanced Melanoma in Sweden
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Hospitalization and Emergency Department Utilization in Patients With Advanced Melanoma Receiving Pembrolizumab vs. Ipilimumab Plus Nivolumab in US Academic Centers
Journal of Medical Economics
Health Policy
Pcn190 - Cost-Effectiveness of Nivolumab + Ipilimumab in First-Line Treatment of Advanced or Metastatic Renal Cell Carcinoma in the Netherlands
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Ipilimumab Combined With Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?
Clinical Cancer Research
Cancer Research
Oncology
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Pcn136 - A Cost-Effectiveness Analysis of Nivolumab in Combination With Ipilimumab for the Treatment of Advanced Renal Cell Carcinoma in Canada
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Nivolumab Plus Ipilimumab Achieves Responses in dMMR/MSI-H Tumors
Cancer Discovery
Oncology
Bevacizumab Plus Ipilimumab in Patients With Metastatic Melanoma
Cancer immunology research
Cancer Research
Immunology
Severe Hemophagocytic Lymphohistiocytosis in a Melanoma Patient Treated With Ipilimumab + Nivolumab
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
